Short Interest in Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Increases By 215.5%

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 50,800 shares, an increase of 215.5% from the November 30th total of 16,100 shares. Based on an average trading volume of 200,500 shares, the short-interest ratio is currently 0.3 days. Currently, 6.0% of the shares of the company are sold short.

Lipella Pharmaceuticals Trading Up 5.1 %

Shares of NASDAQ:LIPO traded up $0.16 during mid-day trading on Thursday, reaching $3.32. The company had a trading volume of 166,281 shares, compared to its average volume of 166,970. Lipella Pharmaceuticals has a one year low of $2.21 and a one year high of $12.00. The company’s 50-day moving average price is $2.95 and its 200-day moving average price is $3.58. The firm has a market cap of $4.01 million, a price-to-earnings ratio of -0.78 and a beta of 0.38.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).